HALEOS LABS LIMITED (HALEOSLABS) fundamentals
HALEOS LABS LIMITED is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as HALEOSLABS (ISIN INE320X01016). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What HALEOS LABS LIMITED does
Haleos Labs Limited, formerly, SMS Lifesciences India Limited, is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph. Eur / IP, Famotidine USP / Ph. Eur / IP, Sildenafil Citrate USP / Ph. Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph. Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. Its intermediate offerings include Ranitidine HCl Intermediates, Rizatriptan Intermediates and Imidapril Intermediates. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center is at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private Limited.
Valuation and market data
| Last close | ₹1475.00 |
|---|---|
| Market capitalisation | ₹446 crore |
| Enterprise value | ₹501 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.08 |
| Price to sales (TTM) | 1.36 |
| Book value per share | ₹709.59 |
| Dividend yield | 10.17% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Aug 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹302 crore | ₹25 crore | ₹18 crore | 58.80 |
| Mar 2025 | ₹337 crore | ₹30 crore | ₹21 crore | 70.69 |
| Mar 2024 | ₹304 crore | ₹19 crore | ₹13 crore | 43.22 |
| Mar 2023 | ₹318 crore | ₹18 crore | ₹13 crore | 43.72 |
| Mar 2022 | ₹347 crore | ₹33 crore | ₹25 crore | 83.95 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 72.1% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.3% |
| Retail and others | 27.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.